JP2023547475A5 - - Google Patents
Info
- Publication number
- JP2023547475A5 JP2023547475A5 JP2023526313A JP2023526313A JP2023547475A5 JP 2023547475 A5 JP2023547475 A5 JP 2023547475A5 JP 2023526313 A JP2023526313 A JP 2023526313A JP 2023526313 A JP2023526313 A JP 2023526313A JP 2023547475 A5 JP2023547475 A5 JP 2023547475A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- alkoxy
- alkyl
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063107853P | 2020-10-30 | 2020-10-30 | |
| US63/107,853 | 2020-10-30 | ||
| PCT/IB2021/060043 WO2022091028A1 (en) | 2020-10-30 | 2021-10-29 | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023547475A JP2023547475A (ja) | 2023-11-10 |
| JP2023547475A5 true JP2023547475A5 (cg-RX-API-DMAC7.html) | 2024-10-24 |
Family
ID=81382005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526313A Pending JP2023547475A (ja) | 2020-10-30 | 2021-10-29 | Betブロモドメイン阻害剤及びナトリウム依存性グルコース輸送体2阻害剤の組み合わせを用いて腎機能を改善するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12673059B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4236955A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023547475A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230098275A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116390721A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021368618B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3197706A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301831A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004671A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202233194A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022091028A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12551484B2 (en) | 2019-11-05 | 2026-02-17 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| AU2021368618B2 (en) | 2020-10-30 | 2025-02-27 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007016525A2 (en) | 2005-07-29 | 2007-02-08 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
| NZ617779A (en) | 2009-03-18 | 2015-08-28 | Resverlogix Corp | Novel anti-inflammatory agents |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| CN106075451A (zh) | 2009-05-27 | 2016-11-09 | 阿斯利康(瑞典)有限公司 | 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法 |
| PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| PL2986304T3 (pl) | 2013-04-18 | 2022-05-02 | Boehringer Ingelheim International Gmbh | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania |
| BR112016003584A8 (pt) | 2013-08-21 | 2018-01-30 | Resverlogix Corp | composições farmaceuticas e uso das mesmas para regressão de placa acelerada |
| KR20160043118A (ko) | 2013-08-21 | 2016-04-20 | 리스버로직스 코퍼레이션 | 가속화된 경화반 퇴행을 위한 조성물 및 치료방법 |
| CN105939728A (zh) * | 2014-01-31 | 2016-09-14 | 詹森药业有限公司 | 用于治疗和预防肾病和脂肪肝病的方法 |
| CN114984016A (zh) | 2015-03-13 | 2022-09-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
| JP6849804B2 (ja) | 2016-12-09 | 2021-03-31 | クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド | ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途 |
| US11419883B2 (en) | 2017-05-05 | 2022-08-23 | The Regents Of The University Of California | Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes |
| US20190031774A1 (en) | 2017-06-09 | 2019-01-31 | Sanofi Biotechnology | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
| US12551484B2 (en) | 2019-11-05 | 2026-02-17 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| KR20220124736A (ko) | 2020-01-08 | 2022-09-14 | 리스버로직스 코퍼레이션 | Bet 브로모도메인 억제제 및 디펩티딜 펩티다아제 4 억제제의 조합을 이용해 주요 심혈관 이상 반응(mace)을 치료 및/또는 예방하는 방법 |
| EP4236957A4 (en) | 2020-10-30 | 2024-08-07 | Resverlogix Corp. | METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR |
| AU2021368618B2 (en) | 2020-10-30 | 2025-02-27 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
-
2021
- 2021-10-29 AU AU2021368618A patent/AU2021368618B2/en active Active
- 2021-10-29 CA CA3197706A patent/CA3197706A1/en active Pending
- 2021-10-29 TW TW110140217A patent/TW202233194A/zh unknown
- 2021-10-29 EP EP21885492.5A patent/EP4236955A4/en active Pending
- 2021-10-29 KR KR1020237018039A patent/KR20230098275A/ko active Pending
- 2021-10-29 WO PCT/IB2021/060043 patent/WO2022091028A1/en not_active Ceased
- 2021-10-29 CN CN202180072395.4A patent/CN116390721A/zh active Pending
- 2021-10-29 JP JP2023526313A patent/JP2023547475A/ja active Pending
- 2021-10-29 MX MX2023004671A patent/MX2023004671A/es unknown
- 2021-10-29 IL IL301831A patent/IL301831A/en unknown
- 2021-10-29 US US18/032,450 patent/US12673059B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10016426B2 (en) | Pharmaceutical compositions for substituted quinazolinones | |
| JP2006523216A5 (cg-RX-API-DMAC7.html) | ||
| JP7617898B2 (ja) | Eyp001を使用した改善された処置 | |
| CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 | |
| JP2023500685A5 (cg-RX-API-DMAC7.html) | ||
| JP2022541503A (ja) | Fxrアゴニストを使用した肝疾患の組み合わせ処置 | |
| WO2019046287A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | |
| JP2006518731A5 (cg-RX-API-DMAC7.html) | ||
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| JP2023526567A5 (cg-RX-API-DMAC7.html) | ||
| WO2026067059A1 (zh) | Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途 | |
| US8673930B2 (en) | Pyrimidylaminobenzamide derivatives for systemic mastocytosis | |
| US12478614B2 (en) | Inhibitors of glutathione s-transferases (GSTs) and NAD(P)H:quinone oxidoreductase 1 (NQO1), pharmaceutical compositions, and uses in managing cancer | |
| EP3957310B1 (en) | Composition comprising sotagliflozin and a tyrosine kinase activity inhibitor for use in the treatment of cancer | |
| CN115397415A (zh) | 乳腺癌治疗剂 | |
| US20240277722A1 (en) | Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent | |
| AU2002309211B2 (en) | Treatment of renal fibrosis | |
| JP2023509186A5 (cg-RX-API-DMAC7.html) | ||
| JP2009506043A5 (cg-RX-API-DMAC7.html) | ||
| JP2022502378A5 (cg-RX-API-DMAC7.html) | ||
| JP7571024B2 (ja) | 抗ccr4抗体抵抗性のがんの治療剤 | |
| AU2002309211A1 (en) | Treatment of renal fibrosis | |
| CN116390721A (zh) | 用于用bet溴结构域抑制剂和钠依赖性葡萄糖转运2抑制剂的组合改善肾功能的方法 | |
| JP2023549703A5 (cg-RX-API-DMAC7.html) | ||
| JP2021534208A (ja) | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |